Raleigh pharma with acquire-and-develop strategy launches clinical trial


In a busy first year, a Raleigh biopharma has acquired another firm, landed a roughly $50 million federal contract and begun dosing patients in a clinical trial.

Previous Covid may have peaked in Oregon but health leaders urge vigilance
Next Dallas-based Steward Health Care and HCA call off deal for five Utah hospitals after FTC complaint